• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.

作者信息

Tsukamoto Shinji, Kurematsu Yukako, Honoki Kanya, Kido Akira, Somekawa Satoshi, Kaya Daisuke, Sadamitsu Tomomi, Fukui Hiroshi, Tanaka Yasuhito

机构信息

Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Nara, Japan.

Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, Kashihara, Nara, Japan.

出版信息

J Orthop Sci. 2016 May;21(3):403-6. doi: 10.1016/j.jos.2015.06.012. Epub 2015 Jun 30.

DOI:10.1016/j.jos.2015.06.012
PMID:26740452
Abstract
摘要

相似文献

1
Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.化疗对沃纳综合征晚期软组织肉瘤的严重毒性：异环磷酰胺诱发的伴中枢性尿崩症的脑病。
J Orthop Sci. 2016 May;21(3):403-6. doi: 10.1016/j.jos.2015.06.012. Epub 2015 Jun 30.
2
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.异环磷酰胺两种研究性给药方案与标准剂量阿霉素治疗晚期或转移性软组织肉瘤的Ⅲ期试验：欧洲癌症研究与治疗组织软组织和骨肉瘤研究组的研究
J Clin Oncol. 2007 Jul 20;25(21):3144-50. doi: 10.1200/JCO.2006.09.7717.
3
Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience.马司钠、多柔比星、异环磷酰胺和达卡巴嗪（MAID）联合化疗治疗腹膜后肉瘤：单中心经验。
Anticancer Res. 2024 Jul;44(7):3213-3220. doi: 10.21873/anticanres.17137.
4
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.优化晚期软组织肉瘤患者的临床治疗：高剂量持续输注异环磷酰胺和多柔比星联合方案的Ⅱ期研究。
Chemotherapy. 2011;57(3):217-24. doi: 10.1159/000326466. Epub 2011 May 18.
5
Advances in chemotherapy for patients with extremity soft tissue sarcoma.肢体软组织肉瘤患者化疗的进展
Orthop Clin North Am. 2006 Jan;37(1):15-22. doi: 10.1016/j.ocl.2005.07.001.
6
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.采用异环磷酰胺与阿霉素联合化疗治疗晚期软组织肉瘤。
J Surg Oncol. 2000 Jan;73(1):12-6.
7
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.欧洲癌症研究与治疗组织的1期研究，确定聚乙二醇化脂质体阿霉素（楷莱）联合异环磷酰胺用于既往未接受治疗的晚期或转移性软组织肉瘤成年患者的安全性。
Eur J Cancer. 2006 Sep;42(14):2303-9. doi: 10.1016/j.ejca.2006.04.011. Epub 2006 Aug 7.
8
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
J Clin Oncol. 1995 Jul;13(7):1600-8. doi: 10.1200/JCO.1995.13.7.1600.
9
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.多柔比星与CYVADIC方案及多柔比星联合异环磷酰胺用于晚期软组织肉瘤一线治疗的比较：欧洲癌症研究与治疗组织软组织和骨肉瘤组的一项随机研究
J Clin Oncol. 1995 Jul;13(7):1537-45. doi: 10.1200/JCO.1995.13.7.1537.
10
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].[MAID方案治疗晚期软组织肉瘤的初步结果]
Ai Zheng. 2002 Aug;21(8):907-9.

引用本文的文献

1
Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene.一名患有腹膜后脂肪肉瘤且携带WRN基因种系突变的患者，对基于异环磷酰胺和阿霉素的化疗出现了加重的肾脏和血液学毒性。
Case Rep Oncol. 2022 Mar 4;15(1):170-175. doi: 10.1159/000521624. eCollection 2022 Jan-Apr.